Pat Cotroneo Biography and Net Worth

CFO of FibroGen

Pat Cotroneo serves as Chief Financial Officer of the Company. Mr. Cotroneo joined us in 2000 as Controller, was promoted to Vice President of Finance, and subsequently promoted to Chief Financial Officer in 2008. Prior to joining us, Mr. Cotroneo was at SyStemix, Inc. where he assumed Controller responsibilities for both SyStemix and Genetic Therapy, Inc. (Novartis subsidiaries) from 1993 to 2000. Prior to SyStemix, he was employed by Deloitte & Touche from 1987 to 1993 in various positions. Mr. Cotroneo received a Bachelor of Science degree with honors from the University of San Francisco and was selected a Louise M. Davies scholar.

What is Pat Cotroneo's net worth?: The estimated net worth of Pat Cotroneo is at least $91.30 thousand as of June 15th, 2021. Mr. Cotroneo owns 11,067 shares of FibroGen stock worth more than $91,303 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Cotroneo may own. Learn More about Pat Cotroneo's net worth.
How do I contact Pat Cotroneo?: The corporate mailing address for Mr. Cotroneo and other FibroGen executives is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. FibroGen can also be reached via phone at (415) 978-1200 and via email at [email protected]. Learn More on Pat Cotroneo's contact information.
Has Pat Cotroneo been buying or selling shares of FibroGen?: Pat Cotroneo has not been actively trading shares of FibroGen during the last quarter. Most recently, Pat Cotroneo sold 162 shares of the business's stock in a transaction on Tuesday, June 15th. The shares were sold at an average price of $640.50, for a transaction totalling $103,761.00. Following the completion of the sale, the chief financial officer now directly owns 11,067 shares of the company's stock, valued at $7,088,413.50. Learn More on Pat Cotroneo's trading history.
Who are FibroGen's active insiders?: FibroGen's insider roster includes Pat Cotroneo (CFO), Thomas Kearns, Jr. (Director), James Schoeneck (Director), and Thane Wettig (Insider). Learn More on FibroGen's active insiders.
Are insiders buying or selling shares of FibroGen?: In the last year, FibroGen insiders bought shares 5 times. They purchased a total of 43,067 shares worth more than $291,484.69. The most recent insider tranaction occured on November, 17th when CEO Thane Wettig bought 2,700 shares worth more than $24,570.00. Insiders at FibroGen own 3.1% of the company. Learn More about insider trades at FibroGen.
Information on this page was last updated on 11/17/2025.

Pat Cotroneo Insider Trading History at FibroGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/15/2021	Sell	162	$640.50	$103,761.00	11,067
12/15/2020	Sell	122	$1,090.00	$132,980.00	10,645
9/15/2020	Sell	122	$1,090.75	$133,071.50	10,889
9/3/2020	Sell	600	$1,272.75	$763,650.00	11,157
6/16/2020	Sell	157	$992.00	$155,744.00	10,842
3/16/2020	Sell	369	$659.00	$243,171.00	9,828
9/17/2019	Sell	128	$1,034.50	$132,416.00	9,777
6/18/2019	Sell	128	$1,078.00	$137,984.00	10,031
3/19/2019	Sell	306	$1,385.25	$423,886.50	9,580
2/28/2019	Sell	591	$1,502.00	$887,682.00	10,715
12/18/2018	Sell	133	$1,027.50	$136,657.50	8,880
9/13/2018	Sell	92	$1,487.50	$136,850.00	9,236
9/10/2018	Sell	40	$1,433.75	$57,350.00	8,816
6/14/2018	Sell	402	$1,486.75	$597,673.50	8,988
6/8/2018	Sell	40	$1,388.75	$55,550.00	9,121
6/4/2018	Sell	240	$1,379.00	$330,960.00	9,212
5/21/2018	Sell	599	$1,376.00	$824,224.00
3/15/2018	Sell	1,681	$1,321.25	$2,221,021.25	6,733
3/13/2018	Sell	237	$1,365.25	$323,564.25	6,733
3/8/2018	Sell	75	$1,328.00	$99,600.00	7,046
2/16/2018	Sell	1,980	$1,399.00	$2,770,020.00	8,295
1/22/2018	Sell	1,000	$1,218.00	$1,218,000.00	8,354
12/11/2017	Sell	114	$1,150.00	$131,100.00	7,354
9/11/2017	Sell	114	$1,236.25	$140,932.50	6,296
8/8/2017	Sell	3,800	$1,265.25	$4,807,950.00	6,934
8/2/2017	Sell	1,133	$849.25	$962,200.25	6,826
7/6/2017	Sell	160	$850.00	$136,000.00	6,694
6/22/2017	Sell	120	$800.00	$96,000.00	6,654
6/19/2017	Sell	220	$750.00	$165,000.00	6,754
6/12/2017	Sell	115	$718.75	$82,656.25	6,534
4/25/2017	Sell	260	$700.00	$182,000.00	6,576
1/11/2017	Sell	260	$600.00	$156,000.00	5,549
12/12/2016	Sell	93	$551.25	$51,266.25	5,289
9/12/2016	Sell	93	$455.50	$42,361.50	5,374
6/15/2016	Sell	71	$412.25	$29,269.75	5,524
5/16/2016	Sell	244	$440.00	$107,360.00	5,674
11/25/2015	Sell	200	$750.00	$150,000.00	4,311
9/15/2015	Sell	43	$698.75	$30,046.25	4,299
9/10/2015	Sell	300	$683.25	$204,975.00	4,290
7/20/2015	Sell	315	$586.75	$184,826.25

Pat Cotroneo Buying and Selling Activity at FibroGen

FibroGen Company Overview

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Today's Range

Now: $8.25

$7.99

$8.55

50 Day Range

MA: $10.28

$8.08

$12.31

2 Week Range

Now: $8.25

$4.85

$21.94

Volume

24,961 shs

Average Volume

39,570 shs

Market Capitalization

$33.41 million

P/E Ratio

0.15

Dividend Yield

N/A

Beta

0.74